Effect of priming of multipotent mesenchymal stromal cells with interferon γ on their immunomodulating properties


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Multipotent mesenchymal stromal cells (MSCs) are widely used for cell therapy, in particular for prophylaxis and treatment of graft-versus-host disease. Due to their immunomodulatory properties, MSCs affect the composition of lymphocyte subpopulations, which depends on the immunological state of the organism and can change in different diseases and during treatment. Administration of MSCs is not always effective. Treatment of MSCs with different cytokines (in particular IFN-γ) leads to enhancement of their immunomodulatory properties. The aim of this study was to investigate sub-populational alterations and activation markers in lymphocytes (activated and non-activated) after interaction with MSCs and MSCs pretreated with IFN-γ (γMSCs) in vitro. Lymphocytes were co-cultured with MSCs or γMSCs for 4 days. The proportion of CD4+ and CD8+ expressing CD25, CD38, CD69, HLA-DR, and PD-1 and distribution of memory and effector subsets were measured by flow cytometry after co-cultivation of lymphocytes with MSCs or γMSCs. The distribution of lymphocyte subpopulations changes during culturing. In non-activated lymphocytes cultured without MSCs, decrease in the proportion of naïve cells and increase in the number of effector cells was observed. That could be explained as activation of lymphocytes in the presence of serum in culturing medium. Co-culturing of lymphocytes with MSCs and γMSCs leads to retention of their non-activated state. Activation of lymphocytes with phytohemagglutinin increases the number of central memory cells and activates marker expression. Interaction with MSCs and γMSCs prevents activation of lymphocytes and keeps their naïve state. Priming with IFN-γ did not induce MSCs inhibitory effect on activation of lymphocytes.

About the authors

N. M. Kapranov

National Research Center for Hematology

Author for correspondence.
Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

Y. O. Davydova

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

I. V. Galtseva

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

N. A. Petinati

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

N. I. Drize

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

L. A. Kuzmina

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

E. N. Parovichnikova

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167

V. G. Savchenko

National Research Center for Hematology

Email: kapranov.n@blood.ru
Russian Federation, Moscow, 125167


Copyright (c) 2017 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies